Dr. Ansell on FDA Approval of Subcutaneous Rituximab in Select Blood Cancers

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.

Related Content:

Mayo ClinicOncLive TVHematologic OncologyNon-Hodgkin LymphomaChronic Lymphocytic Leukemia
Allosteric Inhibitors Targeting PIK3CA May Reduce Treatment Toxicities in Breast Cancer
Dr Bishop on 34-Month Data With Anitocabtagene Autoleucel in R/R Myeloma
Dr Leslie on the 5-Year Follow-Up of the ZUMA-5 Trial in R/R Indolent NHL